George Kemble, PhD
Chief Executive Officer, Chief Scientific Officer
Dr. Kemble joined Sagimet Biosciences (then known as 3-V) in August 2011 as its Chief Scientific Officer and was promoted to Chief Executive Officer in October 2015. As CSO, Dr. Kemble was responsible for directing the medicinal chemistry, research, translational and CMC groups of 3-V and worked on several programs including the lead product candidate, TVB-2640 for oncology. Prior to joining the Company, Dr. Kemble served as the Senior Vice President of R&D and Head of Research at MedImmune, Inc., a subsidiary of Astra-Zeneca PLC. During his tenure, he was responsible for a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.
William McCulloch, MB, ChB, FRCP, FFPM
Chief Medical Officer
Dr. McCulloch (Bill) practiced medicine for seven years in the UK, including post- graduate training in Internal Medicine, Hematology and Oncology, before joining the international pharmaceutical industry in 1984. Since then, his 30+-year career as a senior R&D executive in a variety of large and small companies has afforded him extensive experience in developing and commercializing technologies. Dr. McCulloch’s areas of responsibility have included non-clinical and clinical development, regulatory and medical affairs, licensing and sales force training, with a focus in oncology and serious infectious diseases. He has worked for large pharmaceutical companies (Bristol-Myers and Astra), start-up biotechs (U.S. Bioscience, Sparta Pharmaceuticals) and venture capital firms (Pappas Ventures).
Dr. McCulloch has undertaken all phases of drug and technology development and has been directly involved in the U.S. and Europe in filing INDs/CTAs and NDAs/MAAs, with their requisite face-to-face regulatory meetings, securing Orphan Drug status for compounds and obtaining SBIR and other grant funding for his projects. He held the full time position of Chief Medical Officer at Gloucester Pharmaceuticals, Inc., where he led the regulatory strategy and oversaw the conduct of the pivotal trial which led to FDA approval of their HDAC inhibitor, romidepsin (Istodax®) in November 2009 and the subsequent acquisition of the Company by Celgene Corporation in January, 2010. He holds a medical degree (MB, ChB) from the University of Glasgow in Scotland, is a Fellow of the Royal College of Physicians of Glasgow and also a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.
Chief Financial Officer
Dennis Hom has served as Chief Financial Officer and Head of Corporate Development since October 2017. From April 2014 until joining the Company, Mr. Hom was self-employed as a consultant, providing financial advisory services to a number of biotechnology companies. From January 2013 to March 2014, Mr. Hom was served as the vice president of finance and corporate development at Achaogen, Inc. From April 2011 to April 2012, he was the executive director of corporate development at Amgen Inc., a biotechnology company. From July 2005 to March 2011, Mr. Hom held various positions in mergers and acquisitions, business development and licensing and sales at Novartis, a pharmaceutical and healthcare products company. Prior to Novartis, he worked in investment banking at a number of firms, including six years at J.P. Morgan and predecessor firm Hambrecht & Quist. Mr. Hom holds a B.S. in Biology from the Massachusetts Institute of Technology.
Marie O’Farrell (PhD)
Vice-President of Research and Development
Marie O’Farrell (PhD) is Vice-President of Research and Development at Sagimet and was the Senior Director of Translational Sciences from 2013 to 2016. Dr. O’Farrell started her career in drug development in 1998 at Systemix (Novartis) working on stem cell based gene therapy. Since then she has taken positions of increasing responsibility at several companies, primarily in the areas of metabolic disease and oncology. Dr. O’Farrell has had a successful track record using innovative translational and biomarker strategies to guide clinical development. At Sugen, she lead the clinical oncology biomarker team for the kinase inhibitor sunitinib (SUTENT™). At Phenomix, she led the nonclinical and clinical pharmacology teams for the DPP4 inhibitor dutogliptin to late Phase 3 trials in Type 2 Diabetes and was a member of joint drug development teams with Plexxikon, Forest and Chiesi. Dr. O’Farrell has also led drug development programs at Pathway Therapeutics and Revitope.
Dr. O’Farrell has authored or co-authored over 30 peer-reviewed research articles. She holds a PhD in Biochemistry from University of Manchester (England), an Honors B.Sc. degree from University College Cork (Ireland) and did postdoctoral research at the DNAX Research Institute in Palo Alto.